thiouridine and Xeroderma-Pigmentosum

thiouridine has been researched along with Xeroderma-Pigmentosum* in 2 studies

Other Studies

2 other study(ies) available for thiouridine and Xeroderma-Pigmentosum

Article	Year
Photoactivation of DNA thiobases as a potential novel therapeutic option. Current biology : CB, 2001, Jul-24, Volume: 11, Issue:14 The thiopurines, 6-thioguanine and 6-mercaptopurine, are antileukemic agents that are incorporated into DNA following retrieval by the purine salvage pathway (see [1] for a review). Their toxicity requires active DNA mismatch repair (MMR), and thiopurine resistance is an acknowledged phenotype of MMR-defective cells [2, 3]. In addition to these direct cytotoxic effects, DNA thiobases have distinctive photochemical properties [4], the therapeutic potential of which has not been extensively evaluated. We report here that the thiopyrimidine nucleoside 4-thiothymidine is incorporated into DNA. It does not induce MMR-related toxicity, but it interacts synergistically with UVA light and dramatically sensitizes cultured human cells to very low, nonlethal UVA doses. 4-thiothymidine induced UVA dose enhancements of around 100-fold in DNA repair-proficient cells. Nucleotide excision repair-defective xeroderma pigmentosum cells were sensitized up to 1000-fold, implicating bulky DNA photoproducts in the lethal effect. The synergistic action of thiothymidine plus UVA required thymidine kinase, indicating a selective toxicity toward rapidly proliferating cells. Cooperative UVA cytotoxicity is a general property of DNA thiobases, and 6-thioguanine and 4-thiodeoxyuridine were also UVA sensitizers. Thiobase/UVA treatment may offer a novel therapeutic approach for the clinical management of nonmalignant conditions like psoriasis or for superficial tumors that are accessible to phototherapy. Topics: Cell Line; DNA; DNA Repair; Humans; Mercaptopurine; Phototherapy; Thioguanine; Thiouridine; Ultraviolet Therapy; Xeroderma Pigmentosum	2001
Immunotherapeutic approaches to skin cancer. Hospital practice, 1976, Volume: 11, Issue:11 Topical application of a relatively low concentration of one or more agents to which the patient has previously been sensitized can mobilize cell-mediated immune systems at the site of neoplastic or premalignant lesions. Such treatment has proved to be effective against both primary and metastatic skin lesions. It is also suggested that dermatologic experience may provide a model for other cancer immunotherapies. Topics: Administration, Topical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Basal Cell; Dinitrochlorobenzene; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Macrophages; Nitrogen Mustard Compounds; Quinones; Skin Neoplasms; Thiouridine; Tuberculin; Xeroderma Pigmentosum	1976

Article

Year

Photoactivation of DNA thiobases as a potential novel therapeutic option.

Current biology : CB, 2001, Jul-24, Volume: 11, Issue:14

The thiopurines, 6-thioguanine and 6-mercaptopurine, are antileukemic agents that are incorporated into DNA following retrieval by the purine salvage pathway (see [1] for a review). Their toxicity requires active DNA mismatch repair (MMR), and thiopurine resistance is an acknowledged phenotype of MMR-defective cells [2, 3]. In addition to these direct cytotoxic effects, DNA thiobases have distinctive photochemical properties [4], the therapeutic potential of which has not been extensively evaluated. We report here that the thiopyrimidine nucleoside 4-thiothymidine is incorporated into DNA. It does not induce MMR-related toxicity, but it interacts synergistically with UVA light and dramatically sensitizes cultured human cells to very low, nonlethal UVA doses. 4-thiothymidine induced UVA dose enhancements of around 100-fold in DNA repair-proficient cells. Nucleotide excision repair-defective xeroderma pigmentosum cells were sensitized up to 1000-fold, implicating bulky DNA photoproducts in the lethal effect. The synergistic action of thiothymidine plus UVA required thymidine kinase, indicating a selective toxicity toward rapidly proliferating cells. Cooperative UVA cytotoxicity is a general property of DNA thiobases, and 6-thioguanine and 4-thiodeoxyuridine were also UVA sensitizers. Thiobase/UVA treatment may offer a novel therapeutic approach for the clinical management of nonmalignant conditions like psoriasis or for superficial tumors that are accessible to phototherapy.

Topics: Cell Line; DNA; DNA Repair; Humans; Mercaptopurine; Phototherapy; Thioguanine; Thiouridine; Ultraviolet Therapy; Xeroderma Pigmentosum

2001

Immunotherapeutic approaches to skin cancer.

Hospital practice, 1976, Volume: 11, Issue:11

Topical application of a relatively low concentration of one or more agents to which the patient has previously been sensitized can mobilize cell-mediated immune systems at the site of neoplastic or premalignant lesions. Such treatment has proved to be effective against both primary and metastatic skin lesions. It is also suggested that dermatologic experience may provide a model for other cancer immunotherapies.

Topics: Administration, Topical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Basal Cell; Dinitrochlorobenzene; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Macrophages; Nitrogen Mustard Compounds; Quinones; Skin Neoplasms; Thiouridine; Tuberculin; Xeroderma Pigmentosum

1976